You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The startup wants to serve the 50 percent or so of genetic disease patients who haven't obtained a molecular diagnosis despite extensive testing.
The deal consists of cash, Bionano common stock, and assumption of liabilities. Bionano has also paid off $1.1 million loaned to Lineagen under the CARES act.
The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.
As the firm predicted, second quarter revenues were down due to lab closures associated with COVID-19 and totaled $1.2 million.
Because of coronavirus-related shutdowns of customer labs, the San Diego-based firm saw decreased revenues in all geographic regions, especially outside the US.
The public-private partnership has published a paper on a list of indels larger than 50 bp that is already being used to develop new methods.
Because of COVID-19, the San Diego-based firm said it was unable to ship new instruments and many users were unable to operate their existing ones.
The San Diego-based genome mapping firm's share price fell below $1.00 for 30 consecutive days, triggering a noncompliance notification from Nasdaq.
With the help of Bionano Genomics, Genoox, Rescale, and Amazon, the investigators aim to study 1,000 patients with SARS-CoV-2 to better understand the disease.
The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.
According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.
A number of United Nations agencies push for scientific findings to be made accessible through open science.
Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.
In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.